NEWS DESK

VKTX Stock News, News Score & What It Could Mean

Viking Therapeutics, Inc. - Common Stock (VKTX) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.

HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
70/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$37.81
Trend Context
Mixed / range
Latest briefing

What's happening with VKTX

seekingalpha.com10 Jul 2026

Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX's potential valuation in a rapidly expanding GLP-1 market.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
fxempire.com9 Jul 2026

Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength

Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or decisive breakout above major resistance will likely determine the next trend.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
fool.com7 Jul 2026

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
fool.com
6 Jul 2026
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Read ↗
fool.com
5 Jul 2026
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
Read ↗
fool.com
4 Jul 2026
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
Read ↗
fool.com
3 Jul 2026
Here's Why Viking Therapeutics Stock Surged Higher in June
Read ↗
fool.com
1 Jul 2026
Is Viking Therapeutics Stock Going to $100?
Read ↗
seekingalpha.com
30 Jun 2026
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Read ↗
Earnings news

VKTX earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your VKTX research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK